Cargando…

Novel Targeted Therapies for Advanced Cholangiocarcinoma

Detalles Bibliográficos
Autores principales:	Rizzo, Alessandro, Brandi, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996824/ https://www.ncbi.nlm.nih.gov/pubmed/33652960 http://dx.doi.org/10.3390/medicina57030212

Ejemplares similares

Hot topics in cholangiocarcinoma
por: Brandi, Giovanni
Publicado: (2019)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
por: Rizzo, Alessandro
Publicado: (2021)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
por: Carloni, Riccardo, et al.
Publicado: (2022)

Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy
por: Zhang, Zunyi, et al.
Publicado: (2023)

Targeted Therapies in Advanced Cholangiocarcinoma
por: Storandt, Michael H., et al.
Publicado: (2023)

Targeted therapies in cholangiocarcinoma: light at the end of the tunnel?
por: Amygdalos, Iakovos, et al.
Publicado: (2023)

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
por: Brandi, Giovanni, et al.
Publicado: (2015)

Evolution of the Experimental Models of Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2020)

Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
por: Du, Jiajia, et al.
Publicado: (2023)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy
por: Casadei-Gardini, Andrea, et al.
Publicado: (2023)

Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
por: Yu, James, et al.
Publicado: (2021)

Targeted Therapies for Perihilar Cholangiocarcinoma
por: Gray, Simon, et al.
Publicado: (2022)

Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review
por: Tavolari, Simona, et al.
Publicado: (2023)

Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
por: Gupta, Amol, et al.
Publicado: (2023)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma
por: Zhao, Li-ming, et al.
Publicado: (2023)

Emerging molecular targets and therapy for cholangiocarcinoma
por: Kayhanian, Hamzeh, et al.
Publicado: (2017)

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
por: Carloni, Riccardo, et al.
Publicado: (2023)

The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
por: Palloni, Andrea, et al.
Publicado: (2023)

Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies
por: Acher, Alexandra W., et al.
Publicado: (2021)

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma
por: Renzulli, Matteo, et al.
Publicado: (2021)

Targeting the IL-6 Dependent Phenotype Can Identify Novel Therapies for Cholangiocarcinoma
por: Braconi, Chiara, et al.
Publicado: (2010)

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Programmed Cell Death Pathways in Cholangiocarcinoma: Opportunities for Targeted Therapy
por: Scimeca, Manuel, et al.
Publicado: (2023)

Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies
por: Rizvi, Ali Abbas, et al.
Publicado: (2021)

Perihilar-cholangiocarcinoma: what really matters?
por: Di Benedetto, Fabrizio, et al.
Publicado: (2022)

Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review
por: Vignone, Anthony, et al.
Publicado: (2021)

Therapy for advanced cholangiocarcinoma: Current knowledge and future potential
por: Wang, Mingxun, et al.
Publicado: (2020)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Ovarian Cancer: Advances in Pathophysiology and Therapies
por: Tossetta, Giovanni, et al.
Publicado: (2023)

IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
por: Brandi, Giovanni, et al.
Publicado: (2022)

Advances in the management of cholangiocarcinoma
por: Zori, Andreas G, et al.
Publicado: (2021)

Novel Targeted Therapies for T-Cell Malignancies
por: Tesio, Melania
Publicado: (2022)

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
por: Chong, Dawn Q., et al.
Publicado: (2016)

Changing Perspectives in the Assessment of Resectability of Hilar Cholangiocarcinoma
por: van Gulik, Thomas M., et al.
Publicado: (2007)

Intrinsic and environmental factors in intrahepatic cholangiocarcinoma development
por: Yuan, Detian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lrmf97ftahk7e3heqjbt1litg8